Nestle entered exclusive talks to sell the company’s skin health business to a consortium led by EQT Partners for 10.2 billion Swiss francs ($10.1 billion), as the food group shifts its portfolio in response to changing consumer demands.

To prepare for radiological and nuclear emergencies, the U.S. Department of Health and Human Services (HSS) announced it will work with Argentum Medical LLC to repurpose the company’s commercial Silverlon technology for radiation injuries of the skin.

Bausch Health, formerly Valeant Pharmaceuticals, received tentative U.S. approval to market the plaque psoriasis lotion Bryhali.

Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said.